Spots Global Cancer Trial Database for Study of NMS-1286937 in Adult Patients With Advanced/Metastatic Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of NMS-1286937 in Adult Patients With Advanced/Metastatic Solid Tumors
Official Title: A Phase I Dose Escalation Study of NMS-1286937 Administered to Adult Patients With Advanced/Metastatic Solid Tumors
Study ID: NCT01014429
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to evaluate the safety and tolerability of NMS-1286937, a polo-like-kinase 1 inhibitor, in patients with advanced metastatic solid tumor.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Arizona TGen Clinical Research Services at Scottsdale Heathcare, Scottsdale, Arizona, United States
Contact Details
Name: Mariangela Mariani, Biol Sci D
Affiliation: Nerviano Medical Sciences
Role: STUDY_DIRECTOR
Name: Maria Adele Pacciarini, Biol Sci D
Affiliation: Nerviano Medical Sciences
Role: STUDY_DIRECTOR
Name: Glen J Weiss, MD
Affiliation: Arizona TGen Clinical Reserch Services at Scottsdale Healthcare
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
